Natalia S. Krylova

Natalia S. Krylova

Auto-generated profile, based on publicly available information

Natalia S. Krylova

Pirogov Russian National Research Medical University

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
NKN. S. Krylova
N. S. Krylova
EKE. A. Kovalevskaya
E. A. Kovalevskaya
NPN. G. Poteshkina
N. G. Poteshkina
AДArray Е. Демкина
Array Е. Демкина
FKF. M. Khashieva
F. M. Khashieva
AХArray М. Хашиева
Array М. Хашиева
ВНЕЗАПНАЯ СМЕРТЬ ПРИ ГИПЕРТРОФИЧЕСКОЙ КАРДИОМИОПАТИИ: ПОИСК НОВЫХ ФАКТОРОВ РИСКА

25 October 2021 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
NPN. G. Poteshkina
N. G. Poteshkina
NKN. S. Krylova
N. S. Krylova
AKA. A. Karasev
A. A. Karasev
TNT. A. Nikitina
T. A. Nikitina
ASA. M. Svanadze
A. M. Svanadze
VSV. N. Smorshchok
V. N. Smorshchok
Aim. To assess right heart condition in patients with coronavirus disease 2019 (COVID-19) pneumonia.Material and methods. One hundred and five patients with COVID-19 pneumonia were divided into 3 groups depending on the involvement of lung parenchyma: group I — 0-25%, II — 25-50%, III — 50-75%. The clinical status of patients was assessed using the NEWS2 and SHOKS-COVID scales. A complete blood count and biochemical blood tests were performed to determine the level of N-terminal pro-brain natriuretic peptide (NT-proBNP) and troponin I. Echocardiography was performed to assess the right heart structural, hemodynamic and functional parameters.Results. In patients with COVID-19 pneumonia, with an increase in lung parenchyma involvement, the intensity of systemic inflammatory response increased: C-reactive protein, group I — (4 [1,9; 35] mg/l), in III — (70,5 [33; 144] mg/l) (pI-III=0,012); myocardial stress marker level increased: NT-proBNP, group I — 77 [48; 150] ng/l, group III — 165 [100; 287] ng/l (pI-III=0,047). The dependence of NT-proBNP on C-reactive protein level was revealed (r=0,335, p=0,03). Intergroup comparison did not reveal significant differences between the main right heart functional parameters: TAPSE, Tei index (PW and TDI), FAC of the right ventricle (RV) (p>0,05). However, differences in the tricuspid annular peaks were found as follows: group I — 0,14 [0,12; 0,14] m/s, group II — 0,14 [0,12; 0,15] m/s, group III — 0,16 [0,14; 0,17] m/s (pI-II=0,012, pI-III=0,014) and RV global longitudinal strain: group I — 19,63±7,72%, group III — 27,4±5,93% (pI-III=0,014). The relationship between the RV global longitudinal strain and SHOKS-COVID score was confirmed (r=0,381; p=0,024).Conclusion. Patients with COVID-19 pneumonia showed no signs of right heart dysfunction. The development of RV hyperfunction was noted. Most likely, this is a compensatory mechanism in response to acute RV afterload. NT-proBNP increase under conditions of an inflammatory response may indicate myocardial stress. The results obtained allow to expand our understanding of the right heart condition in patients with COVID-19 pneumonia.

24 March 2023 in Molecular Genetics Microbiology and Virology (Russian version)
Verified
Journal Article
Closed access
AKAnna Klass
Anna Klass
NKN.S. Krylova
N.S. Krylova
ALA.V. Lysenko
A.V. Lysenko
IVIvan Vlasov
Ivan Vlasov
MMM.YU. Maslova
M.YU. Maslova
EFElena Filatova
Elena Filatova
Introduction. Hypertrophic cardiomyopathy (HCM) is considered the most common hereditary heart disease. HCM is a highly heterogeneous disease from a genetic point of view. However, despite the large number of identified pathogenic variants, the cause of the disease remains unclear in more than a quarter of patients. Therefore, it is still relevant to study the prevalence of pathogenic variants leading to the development of HCM, especially in the Russian population. In this regard, the aim of this work was to assess the contribution of pathogenic variants rs200411226 and rs397515905 in the MYBPC3 gene, leading to the substitutions R495Q, R495W, and R495G, to the development of HCM in the Russian population. Material and methods. The sample included 224 patients with HCM of varying severity. The genotypes of the rs200411226 (NM_000256.3:c.1484G>A) and rs397515905 (NM_000256.3:c.1483C>T/G) variants in the MYBPC3 gene (R495Q, R495W, and R495G) were analyzed using real-time PCR for all patients. Results and discussion. The analysis of the prevalence of these pathogenic variants carried out in this work has shown that the R495Q and R495W mutations in our sample occur with a frequency of 0.4% for each mutation, which is generally comparable with the frequencies of these pathogenic variants in other populations. In addition, R495Q and R495W mutations do not appear to lead to severe disease. Conclusion. We failed to identify the pathogenic R495G variant in our sample of patients with HCM. Thus, these mutations by themselves do not significantly contribute to the development of HCM in the Russian population.

24 September 2018 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
ЕKЕ. A. Kovalevskaya
Е. A. Kovalevskaya
NKN. S. Krylova
N. S. Krylova
NPN. G. Poteshkina
N. G. Poteshkina
DFD. V. Fettser
D. V. Fettser
AVA. E. Vanyukov
A. E. Vanyukov
A clinical case presented, of 6-year follow-up of a patient with apical hypertrophic cardiomyopathy (HCMP) and angina syndrome. The challenges discussed, of differential diagnostics of HCMP and coronary heart disease (CHD) in patient with angina and repolarization disorder on ECG. Specifics of the case presented, was hyperdiagnostics of CHD at the onset of clinical presentation, and intact coronary arteries. In 6 years of follow-up this patient developed coronary lesions required the stenting of left anterior descending artery. Comorbid CHD in older age with apical CHD worsened clinical picture and underlined the issue of comorbidity in CHD and HCMP.

1 January 2020 in Consilium Medicum
Verified
Journal Article
Closed access
NKNatalia S. Krylova
Natalia S. Krylova
MMMaria Yu. Maslova
Maria Yu. Maslova
NPNatalia G. Poteshkina
Natalia G. Poteshkina
EKElena A. Kovalevskaya
Elena A. Kovalevskaya
GSGalina B. Selivanova
Galina B. Selivanova
M№Moscow City Clinical Hospital №52
Moscow City Clinical Hospital №52
Hypertrophic cardiomyopathy (HCM) is a genetically determined disease with a morphological abnormality of myocardial contractile proteins, manifested by asymmetric left ventricular myocardial hypertrophy. Currently, there is evidence that the HCM incidence rate in the population can be up to 1:200, as opposed to the traditionally quoted 1:500. In early works on HCM, this disease has been mostly perceived as a pathology of young and middle age with a high risk of sudden cardiac death. Now it is generally accepted that patients with HCM are likely to reach the old or even geriatric age subject to the benign course of the disease. Comorbidity in such patients contributes to the clinical aspect of the disease. The article deals with problem areas of HCM diagnostics in elderly patients with an emphasis on differential diagnosis of HCM and left ventricular hypertrophy as part of hypertension. It contains a discussion of differential diagnosis of ischemic heart disease in HCM. The authors also focus on the specifics of the course of HCM in old age patients and present factors affecting the prognosis for this group of patients.

1 January 2015 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
NKN. S. Krylova
N. S. Krylova
AДArray Е. Демкина
Array Е. Демкина
FKF. M. Khashieva
F. M. Khashieva
EKE. A. Kovalevskaya
E. A. Kovalevskaya
NPN. G. Poteshkina
N. G. Poteshkina
Цель. Выявить факторы, ассоциированные с фибрилляцией/трепетанием предсердий (ФП/ТП) у больных с гипертрофической кардиомиопатией (ГКМП). Материал и методы. В исследование включены 182 больных ГКМП, 103 из которых — мужчины (средний возраст — 59,6±14,6 лет). Диагноз ФП/ТП устанавливался при регистрации ЭКГ или холтеровского мониторирования ЭКГ на основании данных медицинской документации с указанием на наличие в анамнезе ФП/ТП.Результаты. Пароксизмальная или постоянная форма ФП/ТП выявлены у 60 (33%) больных. Пациенты с ФП/ТП были старше по возрасту (64,2±11,2 против 57,3±15,6 лет, р=0,005), с более выраженной клинической симптоматикой (ФКХСН по NYHA2,4±0,8 против 2,1±0,8, р=0,02). У больных с наличием ФП/ТП размер левого предсердия (ЛП) был больше, чем у больных с синусовым ритмом (4,5±0,6 против 4,1 ±0,7 см, р=0,00003). Частота выявления обструкции выносящего тракта левого желудочка (ВТЛЖ) была примерно одинакова в обеих группах (50% против 52,2%, р=0,2), а максимальный градиент давления (PGmax) в ВТЛЖ был вышеубольныхсФП/ТП (46,0±48,0 против 21,8±26,6 мм рт.ст, р=0,02). Выявлена связь наличия ФП/ТП с увеличением возраста (г=0,21, р=0,005), выраженностью клинической симптоматики (г=0,2, р=0,001), увеличением размера ЛП (г=0,44, р=0,04), выраженностью легочной гипертензии (г=0,47, р=0,004), величиной PGmax в ВТЛЖ (г=0,23, р=0,02). Методом бинарной логистической регрессии отобраны 3 наиболее значимые переменные в качестве предикторов ФП/ТП: возраст пациентов, размер ЛП, PGmax в ВТЛЖ. Получена модель, позволяющая определять риск развития ФП/ТП с высокой прогностической значимостью — Хи-квадрат 22,0, df=3 (р=0,00006): ФП/ТП = 0,05307 * Возраст + 0,98065 * ЛП + 0,01516 * PGmax в ВТЛЖ — 8,66. При полученном результате >0 у больного имеется высокий риск развития ФП/ТП, если результат <0 — риск развития ФП/ТП минимален. Заключение. Предложена модель прогнозирования риска развития ФП/ТП у больных ГКМП с использованием трех предикторов: возраста больного, диаметра левого предсердия и максимального градиента давления в ВТЛЖ.